Table 1.

Baseline characteristics and clinical parameters of the patients

(A) Baseline Characteristics of the Participants
	Control	Stable COPD	Acute Exacerbation of COPD	P value
Number	48	48	48
Clinical Features
Male/female	38/10	38/10	38/10	1
Age	63.72±6.12	67.34±8.45	66.19±7.34	0.893
BMI	23.76±5.12	24.85±4.65	23.09±6.34	0.854
Course of COPD (year)	0	4(1,7)	6(2,9)	0.712

(B) Clinical Parameters of the Patients
	Stable COPD	Acute Exacerbation of COPD	P value
GOLD Classification
I	1(2.08%)	2(4.16%)	0.868
II	9(18.95%)	7(14.58%)
III	18(37.5%)	20(41.67%)
IV	20(41.67%)	19(39.58%)
Complicated with cor pulmonale	13(27.1%)	15(31.25%)	0.653
Complication
Coronary heart disease	24(50%)	26(64.17)	0.683
Heart failure	11(22.9%)	14(29.2%)	0.485
Diabetes	8(16.7%)	6(12.5%)	0.563
Hypertension	37(77.1%)	39(81.25%)	0.615
OASAHS	13(27.1%)	12(25%)	0.816
Anemia	4(8.3%)	3(6.25%)	0.695
Smoking index	800(200,1000)	780(200,900)	0.834
Smoking	12(25%)	11(22.92%)	0.811
ICS	46(95.83%)	48(100%)	0.153
Family oxygen therapy	35(72.9%)	37(77.1%)	0.637
The number of aggravations in the past year	1(0,1.75)	1(0.1.25)	0.712
CAT score	26.22±7.12	25.75±6.14	0.834
Laboratory Examination
White blood cell  (*109/L)	7.45±2.13	13.54±3.15	0.033
Neutrophil/lymphocyte count	1.16(0.70–1.65)	2.43(1.34,2.91)	0.041
Hemoglobin (g/L)	131.13±22.14	134.23±12.07	0.791
Platelet (*109/L)	254.14±54.24	289.15±76.65	0.704
Fibrinogen	3.85(3.12,4.75)	5.54(3.78, 4.76)	0.056
D-Dimer	0.45(0.21,0.63)	0.78(0.54,1.67)	0.061
Procalcitonin positive	1(2.08%)	43(89.58%)	<0.01
C-reactive protein	4.00(3.01,4.65)	180.31(90.23,331.56)	<0.01
FEV1%pred	40.91±12.87%	37.58±14.75	0.692